The Future Of


Targeted Delivery of CNS Therapeutics

Convection Enhanced Delivery (CED) is a method used to deliver drugs to specific structures in the brain. Instead of conventional diffusion, where distribution is limited, CED uses bulk flow to deliver therapeutics over a large area and enables therapeutic doses to reach specific brain targets. This technique allows drugs to get through the blood brain barrier to deep brain structures. Micro catheters are used to deliver drugs using CED; at the tip of the catheter a pressure gradient is generated and pushes the drug through the interstitial space allowing for homogenous distribution and maximising the therapeutic effect.

This technique has been and is currently being used in clinical trials to treat a range of neurological conditions, including Parkinson’s Disease, Huntington’s Diseases, Brain Tumours and Fronto Temporal Dementia.

What do we do?

We are bringing transformative therapies to patients with neurological diseases using state of the art technology. Specialising in creating bespoke therapeutic strategies for the direct delivery of gene and other therapies .

World leading experts

The Neurochase team, which includes world leaders in drug delivery to the CNS, is developing globally scalable delivery solutions for the pharma & biotech industry, enabling them to deliver gene and other therapies safely and effectively.
Neurochase Delivery System

Our Services

Alongside our development of the next generation of CNS drug delivery platforms we provide an array of consultancy and training services on direct delivery to the CNS.
Our pre-clinical support service can help you with protocol development, equipment and devices for optimal drug delivery in studies.

As you move into Clinical trials we can help with protocol development, surgical workflow optimisation and surgeon training and from 2025 access to our revolutionary new CED devices.

News & Articles

Brain Tumor Therapy – A New Indication For Hamlet Pharma

Original Article Today, Hamlet Pharma signed a joint development agreement with Neurochase Limited, founded by Professor Steven Gill, a world leading expert in the area of neurosurgery, to develop novel [...]
Read more

AviadoBio Announces Formation of Scientific Advisory Board

AviadoBio, a pioneering, pre-clinical stage, gene therapy company focused on developing and delivering transformative medicines for people with neurodegenerative disorders, announces that it has established a Scientific Advisory Board (SAB) [...]
Read more

CombiGene and Neurochase Preclinical Study

CombiGene’s and Neurochase’s preclinical study provides valuable information for the upcoming long-term studies in toxicology and biodistribution STOCKHOLM — On June 28, 2021, CombiGene (“CombiGene”, “the Company”) announced that the [...]
Read more

Accelerating gene therapy development: from concept to clinic

As gene therapy pioneers begin to tackle systemic diseases and those with a large patient cohort, their focus must increasingly be set on the twin goals of exceptional AAV yields [...]
Read more
© 2024 Neurochase
Privacy Policy